Mesenchymal stem cells therapy in children with end-stage kidney disease

Chronic kidney disease (CKD) is a major health problem worldwide, with increasing incidence and prevalence. While the of CKD in children relatively low, contributes to problems has many long-term effects.1 characterized by gradual decline function over time. The Kidney Disease Improving Global Outcomes (KDIGO) report defined as an abnormality renal structure or decreased glomerular filtration rate (GFR) that lasts more than three months. classified into 5 stages based on GFR value.2 Patients stage V transition from progressive irreversible, terminal, end-stage (ESKD). To date, standard ESKD management been replacement therapy, consisting hemodialysis (HD), peritoneal dialysis (PD), and/or transplantation. Complexity cost care have obvious consequences availability therapy for children, especially developing countries. Dialysis provides only partial functions, clearance fluid balance, but does not cure disease. transplantation curative management, donor pediatric patients remains challenging